

# Stereoselective Total Synthesis of (–)-(6*R*,11*R*,14*R*)-Colletallol via RCM Protocol

Palakodety Radha Krishna,\* D. Venkata Ramana, B. Karunakar Reddy

D-211, Discovery Laboratory, Organic Chemistry Division-III, Indian Institute of Chemical Technology, Hyderabad 500607, India  
 Fax +91(40)27193158; E-mail: prkgenius@iict.res.in

Received 21 August 2009

**Abstract:** The total synthesis of (–)-colletallol via a ring-closing metathesis protocol is reported.

**Key words:** (–)-colletallol, ring-closing metathesis (RCM), Grubbs II catalyst, Jacobsen's hydrolytic kinetic resolution (HKR)


Colletallol (**1**), a diolide belonging to a series of structurally related macrolides, was isolated from plant pathogen *Colletrichum capsici*.<sup>1</sup> This diolide and its congeners attracted the attention of many synthetic organic chemists worldwide since isolation, but only two syntheses of **1** were reported so far, out of which one was an enantioselective total synthesis by Zwanenburg et al.<sup>2</sup> using epoxy diazomethyl ketone as the starting material and its photo-induced rearrangement to 4-hydroxy-2-alkenoate as the useful intermediate en route and the other one being a racemic synthesis way back in 1985.<sup>3</sup> Subsequently, a 14-epimer was synthesized by Fločh et al.<sup>4</sup> using two consecutive Wittig olefination reactions as an alternative methodology to classical macrolactonization strategy. As a part of our ongoing program on the metathesis-based synthesis of natural products,<sup>5</sup> herein we describe a stereoselective total synthesis of natural (–)-colletallol (**1**) via Grubbs catalyst assisted ring-closing metathesis protocol of the corresponding diester derivative **2** (Scheme 1).

The retrosynthetic analysis envisioned for **1** is depicted in Scheme 1, using a ring-closing metathesis (RCM) of the corresponding diester derivative **2** followed by the deprotection of the MOM protecting group. Compound **2** in turn could be synthesized from **3** on PMB deprotection and acryloylation. Compound **3** should be accessible through the esterification of acid **4** with alcohol **5** that were independently synthesized from the commercially available propylene oxide as starting material.


Thus, the synthesis began in the direction of accessing both the acid **4** and the alcohol **5** components independently. Firstly, acid **4** was accessed based on the literature procedure<sup>6</sup> wherein the synthesis of its enantiomer was reported.

Subsequently, alcohol **5** was also prepared from propylene oxide (Scheme 2) using a literature-inspired route.<sup>7</sup> Accordingly, propylene oxide upon Jacobsen's hydrolytic

kinetic resolution<sup>8</sup>/epoxide ring-opening reaction with allyl magnesium chloride and protection of the ensuing hydroxyl group as its silyl ether afforded **6**. The terminal olefin was used in two ways, firstly Sharpless asymmetric dihydroxylation (AD-mix-β, *t*-BuOH–H<sub>2</sub>O (1:1), 48 h) furnished diol **7** (84%) albeit in 63% de. Further purification of **7** led to diminished yields. Consequently, an alternate Jacobsen's hydrolytic kinetic resolution (HKR) based strategy was adopted and the loss in chemical yield was circumvented by a two-step recycling of the resolved diol **7a** into the requisite epoxide **8**.<sup>9</sup> Thus both enhanced chemical and optical yields were met through this strategy. Epoxide **8** obtained by both methods was found to have comparable spectral data. Later, ring-opening reaction<sup>10</sup> (Me<sub>3</sub>S<sup>+</sup>I<sup>-</sup>, THF, –20 °C to r.t., 3 h) of epoxide **8** gave allylic alcohol **9** (85%) which was protected as its MOM ether **10** under conventional conditions. TBS deprotection (TBAF, THF, r.t., 2 h) in **10** furnished the corresponding alcohol **5** (85%) as the suitable intermediate for the next reaction.




**Scheme 1** Retrosynthetic analysis



**Scheme 2** Reagents and conditions: route A: (a) AD-mix- $\beta$ , *t*-BuOH–H<sub>2</sub>O (1:1), 48 h, 84%, 63% de; (b) i) TsCl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, r.t.; ii) K<sub>2</sub>CO<sub>3</sub>, MeOH, r.t., 1 h, 72% (over two steps); route B: (a') i) MCPBA, CHCl<sub>3</sub>, 0 °C to r.t., 2 h, 90%; ii) (*R,R*)-(salen)CoIII(OAc), 0.55 equiv H<sub>2</sub>O, r.t., 18 h; (b') ref. 9; (c) *n*-BuLi, Me<sub>3</sub>S<sup>+</sup>I<sup>–</sup>, THF, –20 °C to r.t., 3 h, 85%; (d) MOMCl, DIPEA, DMAP (cat.) CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to r.t., 8 h, 98%; (e) TBAF, THF, r.t., 2 h, 85%.

Having both the intermediates **4** and **5** in hand, the next task was to couple them as an ester (Scheme 3). Accordingly, esterification (DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, r.t.) of **4** and **5** afforded **3** (80%) which was characterized by its spectral data. For instance, <sup>1</sup>H NMR spectrum of ester **3** revealed the characteristic signals due to the ester-linked proton shifting downfield to  $\delta = 4.90$ – $4.98$  ppm as a multiplet while the rest of the protons resonated at their expected chemical shifts. Also, the characteristic olefinic protons present in conjugation with the  $\alpha,\beta$ -unsaturated ester revealed the  $\alpha$ -proton at  $\delta = 5.57$ – $5.67$  ppm integrating for 1 H, while the  $\beta$ -proton appeared at  $\delta = 6.85$ – $6.94$  ppm. The terminal olefinic protons integrating for 3 H retained their expected chemical shifts. The HRMS was in good agreement {*m/z* calcd for C<sub>23</sub>H<sub>34</sub>O<sub>6</sub>Na [M + Na]<sup>+</sup>: 429.2253; found: 429.2263} with the expected structure. Next, the PMB group was deblocked under DDQ conditions; the corresponding hydroxyl group was acryloylated (acryloyl chloride, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, r.t.) to furnish the crucial intermediate **2** (95%). Diester **2** was then subjected to ring-closing metathesis reaction (Grubbs II, toluene, reflux, 4 h) to afford diolide **11** in good yields albeit as an *E/Z* mixture in a 85:15 ratio.<sup>11</sup> The required *E*-isomer was purified by column chromatography and characterized by its spectral data. For instance, the <sup>1</sup>H NMR spectrum of (*E*)-**11** displayed the absence of chemical shifts due to terminal olefinic protons, the emergence of two nonequivalent  $\alpha$ -protons: one at  $\delta = 5.79$  ppm as a doublet ( $J = 15.1$  Hz) and the other at  $\delta = 5.87$  ppm as a double doublet ( $J = 16.1, 1.4$  Hz); while one of the two  $\beta$ -protons appearing at  $\delta = 6.68$ – $6.75$  ppm as a multiplet and the other one at  $\delta = 6.81$  ppm as a double doublet ( $J = 15.6, 4.3$  Hz) of

the  $\alpha,\beta$ -unsaturated esters marked the formation of the product. The HRMS spectrum displayed the *m/z* [M + Na]<sup>+</sup> 335.1475, calculated 335.1470 for the molecular formula C<sub>16</sub>H<sub>24</sub>O<sub>6</sub>Na. Later, deprotection of MOM ether in **11** under Hannessian conditions<sup>12</sup> resulted in the natural product **1** (95%). The physical and spectroscopic data of synthetic **1** is consistent with the reported values.<sup>1,2,13</sup>



**Scheme 3** Reagents and conditions. a) DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, r.t., 80%; b) (i) DDQ, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to r.t., 95%; (ii) acryloyl chloride, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, 4 h, r.t., 95%; c) Grubbs II (10 mol%), toluene, reflux, 4 h, 80%; d) TMSCl, *n*-Bu<sub>4</sub>N<sup>+</sup>Br<sup>–</sup>, CH<sub>2</sub>Cl<sub>2</sub>, –10 °C to 0 °C, 2 h, 95%.

In summary, synthesis of (–)-colletalol was accomplished via the RCM of the highly substituted diester **2** with Grubbs II catalyst in good yields and selectivity. The key intermediates **4** and **5** were accessed from a common, inexpensive starting material viz. (±)-propylene oxide through simple transformations using Jacobsen's HKR protocol as the means of introducing chirality.

## Acknowledgment

Two of the authors (D. V. R. and B. K. R.) thank the CSIR, New Delhi for the financial support in the form of fellowships.

## References and Notes

- (a) MacMillan, J.; Pryce, R. J. *Tetrahedron Lett.* **1968**, 5497. (b) MacMillan, J.; Simpson, T. J. *J. Chem. Soc., Perkin Trans. 1* **1973**, 1487.
- Dommerholt, F. J.; Thijs, L.; Zwanenburg, B. *Tetrahedron Lett.* **1991**, 32, 1495.
- Wakamatsu, T.; Yamada, S.; Ozaki, Y.; Ban, Y. *Tetrahedron Lett.* **1985**, 26, 1989.
- Amigoni, S. J.; Toupet, L. J.; Le Floch, Y. J. *J. Org. Chem.* **1997**, 62, 6374.
- (a) Radha Krishna, P.; Narsingam, M. *Tetrahedron Lett.* **2004**, 45, 4773. (b) Radha Krishna, P.; Srinivas, P. R. *Tetrahedron* **2007**, 63, 3995. (c) Radha Krishna, P.; Krishnarao, L. *Synlett* **2007**, 1742. (d) Radha Krishna, P.; Srinivas, R. *Tetrahedron: Asymmetry* **2007**, 18, 2197. (e) Radha Krishna, P.; Dayaker, G. *Tetrahedron Lett.* **2007**, 48, 7279. (f) Radha Krishna, P.; Narsingam, M. *Tetrahedron Lett.* **2007**, 48, 8721. (g) Radha Krishna, P.; Srinivas, R. *Tetrahedron: Asymmetry* **2008**, 19, 1160. (h) Radha Krishna, P.; Srinivas, P. R. *Synlett* **2009**, 209.
- Sharma, G. V. M.; Babu, K. V. *Tetrahedron: Asymmetry* **2007**, 18, 2175.

- (7) Liu, J.; Zhang, L.; He, L.; Ma, B.; Pan, X.; She, X. *Tetrahedron: Asymmetry* **2008**, *19*, 906.
- (8) (a) Tokunaga, M.; Larrow, J. F.; Kakiuchi, F.; Jacobsen, E. N. *Science* **1997**, *277*, 936. (b) Schaus, S. E.; Brandes, B. D.; Larrow, J. F.; Tokunaga, M.; Hansen, K. B.; Gould, A. E.; Furrow, M. E.; Jacobsen, E. N. *J. Am. Chem. Soc.* **2002**, *124*, 1307.
- (9) Radha Krishna, P.; Srinivas, R. *Tetrahedron Lett.* **2007**, *48*, 2013.
- (10) Alcaraz, L.; Harnett, J. J.; Mioskowski, C.; Martel, J. P.; Legall, T.; Shin, D.-S.; Falck, J. R. *Tetrahedron Lett.* **1994**, *35*, 5449.
- (11) (a) Lee, C. W.; Grubbs, R. H. *J. Org. Chem.* **2001**, *66*, 7155. (b) Chatterjee, A. K.; Grubbs, R. H. *Angew. Chem. Int. Ed.* **2002**, *41*, 3171. (c) Deiters, A.; Martin, S. *Chem. Rev.* **2004**, *104*, 2199.
- (12) Hanessian, S.; Delorme, D.; Dufresne, Y. *Tetrahedron Lett.* **1984**, *25*, 2515.
- (13) Spectral Data for Selected Compounds  
 Compound **5**: colorless liquid;  $[\alpha]_{\text{D}}^{25} +243.0$  (*c* 0.15, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta = 5.73\text{--}5.58$  (m, 1 H), 5.24–5.13 (m, 2 H), 4.64 (d, *J* = 6.8 Hz, 1 H), 4.48 (d, *J* = 6.8 Hz, 1 H), 4.04–3.96 (m, 1 H), 3.83–3.73 (m, 1 H), 3.35 (s, 3 H), 1.68–1.39 (m, 4 H), 1.17 (d, *J* = 6.0 Hz, 3 H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 138.0, 117.2, 93.7, 77.4, 67.8, 55.4, 34.7, 31.7, 23.4$ . MS (EI): *m/z* = 113 [M – OMOM].  
 Compound **3**: colorless liquid;  $[\alpha]_{\text{D}}^{25} +90.0$  (*c* 0.25, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta = 7.19$  (d, *J* = 8.3 Hz, 2 H), 6.94–6.85 (m, 1 H), 6.80 (d, *J* = 8.3 Hz, 2 H), 5.80 (d, *J* = 15.6 Hz, 1 H), 5.67–5.57 (m, 1 H), 5.23–5.13 (m, 2 H), 4.98–4.90 (m, 1 H), 4.67–4.61 (m, 1 H), 4.49–4.24 (m, 2 H), 4.37 (d, *J* = 11.2 Hz, 1 H), 3.98–3.90 (m, 1 H), 3.78 (s, 3 H), 3.63–3.56 (m, 1 H), 3.3 (s, 3 H), 2.49–2.4 (m, 1 H), 2.37–2.27 (m, 1 H), 1.67–1.54 (m, 4 H), 1.24 (d, *J* = 5.8 Hz, 3 H), 1.18 (d, *J* = 6.3 Hz, 3 H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 165.9, 145.1, 137.9, 129.0, 123.5, 117.4, 113.7, 93.6, 77.0, 73.1, 70.6, 70.1, 55.3, 55.2, 39.2, 31.7, 31.1, 19.9, 19.6$ . HRMS: *m/z* calcd for C<sub>23</sub>H<sub>34</sub>O<sub>6</sub>Na [M + Na]<sup>+</sup>: 429.2253; found: 429.2263.  
 Compound **2**: colorless liquid;  $[\alpha]_{\text{D}}^{25} +155.9$  (*c* 0.5, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta = 6.92\text{--}6.84$  (m, 1 H), 6.39 (d, *J* = 17.0 Hz, 1 H), 6.09 (d, *J* = 17.0, 10.2 Hz, 1 H), 5.90–5.80 (m, 2 H), 5.70–5.61 (m, 1 H), 5.24–5.17 (m, 2 H), 5.12–5.06 (m, 1 H), 4.99–4.93 (m, 1 H), 4.68 (d, *J* = 6.8 Hz, 1 H), 4.52 (d, *J* = 6.8 Hz, 1 H), 4.00–3.94 (m, 1 H), 3.36 (s, 3 H), 2.55–2.44 (m, 2 H), 1.69–1.55 (m, 4 H), 1.28 (d, *J* = 6.3 Hz, 3 H), 1.24 (d, *J* = 6.3 Hz, 3 H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 165.7, 165.5, 143.2, 137.9, 130.7, 128.5, 124.5, 117.5, 93.7, 77.0, 71.4, 69.3, 55.4, 38.3, 31.7, 31.2, 20.3, 19.6$ . HRMS: *m/z* calcd for C<sub>18</sub>H<sub>28</sub>O<sub>6</sub>Na [M + Na]<sup>+</sup>: 363.1783; found: 363.1773.  
 Compound **11**: brown colored liquid;  $[\alpha]_{\text{D}}^{25} +123.8$  (*c* 0.06, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta = 6.75\text{--}6.71$  (dd, *J* = 16.1, 5.4 Hz, 1 H), 6.70–6.63 (m, 1 H), 5.82 (d, *J* = 16.1 Hz, 1 H), 5.71 (d, *J* = 15.6 Hz, 1 H), 5.28–5.22 (m, 1 H), 5.16–5.11 (m, 1 H), 4.56 (s, 2 H), 4.44–4.40 (m, 1 H), 3.32 (s, 3 H), 2.54–2.48 (m, 2 H), 2.05–1.97 (m, 2 H), 1.81–1.74 (m, 1 H), 1.67–1.61 (m, 1 H), 1.45 (d, *J* = 6.3 Hz, 3 H), 1.17 (d, *J* = 6.8 Hz, 3 H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 168.3, 165.5, 149.2, 143.6, 126.2, 122.1, 94.5, 74.0, 69.1, 68.3, 55.4, 40.6, 27.7, 26.5, 20.7, 17.5$ . HRMS: *m/z* calcd for C<sub>16</sub>H<sub>24</sub>O<sub>6</sub>Na [M + Na]<sup>+</sup>: 335.1470; found: 335.1475.  
 Compound **1**: colorless syrup;  $[\alpha]_{\text{D}}^{25} -85.5$  (*c* 0.1 CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta = 6.81$  (dd, *J* = 15.6, 4.3 Hz, 1 H), 6.75–6.68 (m, 1 H), 5.87 (dd, *J* = 16.1, 1.4 Hz, 1 H), 5.79 (d, *J* = 15.1 Hz, 1 H), 5.26–5.16 (m, 2 H), 4.60 (s, 1 H), 2.53 (m, 1 H), 2.38–2.24 (m, 2 H), 2.17 (d, *J* = 2.9 Hz, 1 H), 1.79–1.67 (m, 2 H), 1.36 (d, *J* = 6.3 Hz, 3 H), 1.19 (d, *J* = 6.8 Hz, 3 H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 170.0, 165.6, 150.9, 143.5, 126.2, 121.3, 70.4, 69.1, 68.4, 40.6, 32.2, 29.1, 20.6, 17.4$ . HRMS: *m/z* calcd for C<sub>14</sub>H<sub>20</sub>O<sub>5</sub>Na [M + Na]<sup>+</sup>: 291.1208; found: 291.1210.

Copyright of Synlett is the property of Georg Thieme Verlag Stuttgart and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.